by Steven A.
Buechler, Yesim Gökmen–Polar, Sunil S. Badve
The Breast: February 2019, Volume 43, Pages 74-80
Highlights:
•EarlyR gene signature uses expression of 5 genes
to stratify ER + breast cancer patients by prognosis.
•EarlyR has been previously validated in 2
randomized clinical trials.
•The current study documents the ability of EarlyR
to predict pathological complete response (pCR).
•EarlyR predicts survival in NACT-treated
ER + patients.
•EarlyR is both a prognostic assay and a predictive
assay.
